title: Does WOQ-9 help to recognize symptoms of non-motor wearing-off in Parkinson's disease?
abstract: EWO (Epidemiology of Wearing-Off symptoms among the population of Parkinson's disease (PD) patients on L-DOPA) is a multicentric, non-interventional, epidemiological and exploratory trial, focused on patients with PD who are treated with L-DOPA. The primary objective is the estimation of wearing-off symptoms (based on WOQ-9 questionnaire and assessment by neurologists) among PD patients who are treated with L-DOPA. From September 30, 2007 to June 30, 2008 altogether 563 valid records of PD patients were collected in movement disorders centers (Level A and Level B centers). Wearing-off symptoms were observed in 66.7% of PD patients (neurologists' assessment) and in 90.6% of PD patients (WOQ-9 questionnaire). The biggest discrepancy was found in PD patients treated with L-DOPA for 0-2 years. The probability of detecting wearing-off by the neurologists strongly correlated with the highest number of positive responses in the WOQ-9 marked by PD patients. There was significant difference in the diagnosis of wearing-off between Level A centers (77.7%) and Level B centers (62.0%). When motor and non-motor symptoms in the WOQ-9 were considered, the difference between neurologists came from the detection of non-motor symptoms (lower in the Level B centers). The neurologists' assessment of wearing-off symptoms and PD patients' subjective evaluation of the WOQ-9 is based on the experience of the neurologist and on the detection of the non-motor symptoms of wearing-off. Careful explanation of the WOQ-9 questionnaire and improved awareness of the non-motor symptoms of wearing-off is strongly suggested.
authors.affiliation: Movement Disorders Centre Brno and First Department of Neurology, Faculty of Medicine Masaryk University Brno, St. Anne's Hospital Pekarska 53, 656 91 Brno, Czech Republic. martin.bares@fnusa.cz
authors.forename: Martin
authors.initials: M
authors.lastname: Bareš
authors.forename: Irena
authors.initials: I
authors.lastname: Rektorová
authors.forename: Robert
authors.initials: R
authors.lastname: Jech
authors.forename: Kateřina
authors.initials: K
authors.lastname: Farníková
authors.forename: Jan
authors.initials: J
authors.lastname: Roth
authors.forename: Evžen
authors.initials: E
authors.lastname: Růžička
authors.forename: Petr
authors.initials: P
authors.lastname: Kaňovský
authors.forename: Ivan
authors.initials: I
authors.lastname: Rektor
authors.forename: Tomáš
authors.initials: T
authors.lastname: Pavlík
authors.forename: Leona
authors.initials: L
authors.lastname: Uhlířová
authors.forename: Jaroslav
authors.initials: J
authors.lastname: Vydlák
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004185:Disability Evaluation; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D011795:Surveys and Questionnaires
chemical_list: D007980:Levodopa